In a groundbreaking advancement that promises to reshape our understanding of fibrotic processes related to skeletal implants, researchers have identified Gremlin-1 (GREM1) as a pivotal mediator in peri-implant fibrosis through its activity in leptin receptor-expressing skeletal cells. This discovery, published in Nature Communications in 2026, unveils a novel cellular mechanism that could open new avenues for therapeutic intervention against fibrosis—a common and challenging complication that undermines the success of orthopedic and dental implants.
Peri-implant fibrosis, characterized by excessive fibrous tissue formation around an implant site, frequently leads to implant failure and subsequent surgical revision. Until now, the underlying molecular drivers of this fibrotic response were poorly understood, limiting treatment options primarily to mechanical or symptomatic management. The study conducted by Suhardi, Oktarina, Niu, and colleagues breaks new ground by linking GREM1—a known antagonist of bone morphogenetic proteins (BMPs)—to the fibrotic cascade within a very specific cellular context.
Leptin, a hormone well-recognized for its role in energy homeostasis, also exerts influence on skeletal biology through leptin receptors present on various bone-associated cells. The investigators focused on leptin receptor-expressing (LepR+) skeletal cells, a subpopulation known to contribute to bone remodeling and regeneration. Using sophisticated genetic models and molecular assays, they demonstrated that GREM1 is not merely a passive factor but actively orchestrates the fibrotic remodeling process by modulating signaling pathways within LepR+ skeletal cells during implant integration.
The research team employed lineage tracing and conditional knockout strategies, allowing for selective manipulation of GREM1 expression in LepR+ skeletal cells in vivo. Loss of GREM1 in this cellular subset resulted in a marked reduction in fibrotic tissue development surrounding implants, accompanied by improved implant integration and mechanical stability. Such compelling evidence positions GREM1 as a key driver of peri-implant fibrosis, acting through a previously uncharacterized autocrine and paracrine network.
Mechanistically, the study highlights the interplay between GREM1 and BMP signaling pathways. While BMPs are conventionally seen as promoters of bone formation, GREM1, by antagonizing BMPs, creates an environment conducive to fibrosis rather than osteogenesis. This modulation appears finely tuned within LepR+ cells, dictating the balance between regenerative healing and pathological fibrosis at implant sites.
Crucially, the findings provide insights into the inflammatory milieu often accompanying implant surgeries. The presence of GREM1 correlated with heightened expression of profibrotic cytokines and extracellular matrix components, indicating that the fibrotic response driven by LepR+ cells is tightly linked to both cellular signaling and tissue-level remodeling. This dual action underscores GREM1’s role as more than a mere molecular marker—it’s an active participant orchestrating the fibrotic program.
From a translational perspective, targeting GREM1 or its downstream signaling pathways in LepR+ skeletal cells could herald a new era in biomaterial design and postoperative management. By modulating this axis, it may become feasible to suppress fibrotic scarring while preserving or enhancing bone regeneration, thereby improving implant longevity and patient outcomes.
The research team supported their conclusions with quantitative histological analyses and biomechanical testing, validating that absence or inhibition of GREM1 led to substantially diminished fibrotic encapsulation and superior mechanical integration of implants within rodent models. These robust data sets establish a causal role for GREM1 and underscore the therapeutic potential of interference in its signaling pathway.
Furthermore, the study contextualizes GREM1 expression within the broader spectrum of skeletal stem/progenitor cells, suggesting that fibrotic mediation is a finely tuned process involving specific cellular niches rather than a generalized tissue response. This reframing challenges existing paradigms and encourages the scientific community to rethink fibrosis at the cellular microenvironment level.
Critically, the identification of LepR+ cells as principal effectors modifies our view of peri-implant fibrotic pathophysiology. These cells, already implicated in skeletal repair mechanisms, now emerge as double-edged swords capable of switching between regenerative and fibrotic programs depending on the molecular signals they receive, such as those regulated by GREM1.
The study also hints at potential biomarkers for predicting and monitoring fibrotic progression post-implantation. GREM1 levels within skeletal niches may serve as prognostic indicators, enabling early intervention strategies and personalized treatment plans to mitigate fibrotic outcomes before they impair implant function.
Moreover, this research has implications beyond skeletal implants, as fibrosis is a hallmark in multiple pathological contexts including organ fibrosis and cancer stroma formation. Understanding GREM1’s fibrotic role may inspire cross-disciplinary approaches to fibrosis management across various tissues.
Importantly, the research methodology utilized cutting-edge single-cell transcriptomics and proteomics to delineate the cellular heterogeneity of skeletal niches, providing a high-resolution map of GREM1 activity and its impact on cell fate decisions. Such granularity advances the field’s ability to precisely target fibrosis without impairing beneficial regenerative processes.
As the prevalence of joint replacements and dental implants escalates worldwide, complications stemming from fibrosis represent substantial clinical and economic burdens. The elucidation of GREM1’s central role offers hope for novel molecular therapies that could transform implant medicine and improve quality of life for millions.
In summary, Suhardi and collaborators have delivered a meticulous and paradigm-shifting exploration into the cellular underpinnings of peri-implant fibrosis. By highlighting GREM1’s action in leptin receptor-expressing skeletal cells, they have identified a specific molecular target with broad therapeutic implications and set the stage for innovative strategies to control fibrosis and enhance implant success.
The implications of this study extend far beyond the operating room. They invite a reconsideration of fibrotic processes in tissue engineering, regenerative medicine, and chronic disease management, promising a future where implants not only restore function but do so without the shadow of fibrosis.
As the scientific community builds on these findings, it will be fascinating to observe how this newfound knowledge shapes the next generation of biomaterials and fibrosis treatments, potentially ushering in an era where fibrotic complications are significantly diminished, and patient outcomes are profoundly improved.
Subject of Research:
The role of Gremlin-1 (GREM1) in mediating peri-implant fibrosis through activity in leptin receptor-expressing skeletal cells.
Article Title:
GREM1 acts in leptin receptor-expressing skeletal cells to mediate peri-implant fibrosis.
Article References:
Suhardi, V.J., Oktarina, A., Niu, Y. et al. GREM1 acts in leptin receptor-expressing skeletal cells to mediate peri-implant fibrosis. Nat Commun (2026). https://doi.org/10.1038/s41467-026-70111-0
Image Credits: AI Generated
